Monitor this situation.

Unsubscribe anytime.

[SITUATION] · [QUIET] · [HEALTH]

2 clusters · 7 sources · 5 days · First seen about 1 month ago · Last updated 27 days ago

Development of glucose-responsive probiotics for diabetes

Overview

Researchers from East China Normal University have developed an engineered probiotic, named GIFT, designed to treat diabetes through a “sense and respond” mechanism. Published in the journal Nature, the study describes how the probiotic uses a synthetic gene circuit and the HexR regulatory protein to act as a molecular switch. When glucose levels rise, the system triggers the production of GLP-1 analogues, such as semaglutide, to lower blood sugar; production ceases once levels normalize.

In animal trials, the system showed efficacy in mice by improving insulin sensitivity and reducing organ damage. In cynomolgus monkeys with type 2 diabetes, oral administration maintained stable blood glucose levels over five weeks without toxic or inflammatory reactions. While these results are promising for mitigating side effects of long-term semaglutide use, further research is necessary to confirm efficacy in humans.

Entities

Nature · East China Normal University · GIFT · Ye Haifeng · Nature Communications

Timeline

27 days ago

[HEALTH] 3 sources
Medical research advances in metabolic health and diabetes treatment
New research explores metabolic health through fasting-mimicking diets and the development of genetically modified probiotics that automatically regulate glucose levels in diabetic animal models.
about 1 month ago

[HEALTH] 2 sources
Chinese researchers develop glucose-responsive oral probiotics for diabetes
Researchers in China have developed GIFT, an engineered oral probiotic that senses glucose levels to automatically release GLP-1 medication, potentially reducing side effects of traditional diabetes treatments.

Sources

afamily.vn · cafebiz.vn · cafef.vn · ithome.com · kenh14.vn · kienthuc.net.vn · unwire.hk